Beckman Coulter MicroScan B1016-138 Manuel D'utilisation page 9

Antimicrobics
Ofloxacin (CLSI M100-S14)
Staphylococci
β-hemolytic Streptococci (S. agalactiae, Group B)
Oxacillin
Coagulase-negative Staphylococci
S. aureus/S. lugdunensis
Penicillin G
Staphylococci
6
L. monocytogenes
Enterococci
β-hemolytic Streptococci (S. agalactiae, Group B)
Viridans Group Streptococci (S. bovis group)
4
Piperacillin/Tazobactam
Staphylococci (CLSI M100-S22)
9
Pristinamycin
Staphylococci, Enterococci,
β-hemolytic Streptococci (S. agalactiae, Group B), and
Viridans Group Streptococci (S. bovis group)
Rifampin
9
Staphylococci
Enterococci
β-hemolytic Streptococci (S. agalactiae, Group B)
Viridans Group Streptococci (S. bovis group)
Synercid
Staphylococci
Enterococci
E. faecium
β-hemolytic Streptococci (S. agalactiae, Group B)
Teicoplanin
Staphylococci
S. aureus
Enterococci
Tetracycline
Staphylococci
Enterococci
β-hemolytic Streptococci (S. agalactiae, Group B)
Viridans Group Streptococci (S. bovis group)
Ticarcillin/K Clavulanate
Staphylococci (CLSI M100-S22)
Tobramycin – Staphylococci
Trimethoprim/Sulfamethoxazole – Staphylococci
Vancomycin
S. aureus
Coagulase-negative Staphylococci
Enterococci
β-hemolytic Streptococci (S. agalactiae, Group B)
Viridans Group Streptococci (S. bovis group)
30
1. Based on EUCAST V6.0.
2. Based on Interpretive Breakpoints as indicated in CLSI document M100-S26 and M45-A2. There are antimicrobials included in this panel that are not
proven to be safe and effective in treating clinical infections for all organisms tested. For reporting of antimicrobial results which have shown to be active
against organisms groups in vitro or in clinical infections refer to CLSI M100, Tables 1 and 2 or the pharmaceutical package insert.
3. OTHER therapy may be based on SFM, Mensura, FDA, or Manufacturers Breakpoints. Please refer to subsequent footnotes for details.
4. For beta-lactamase negative enterococci, refer to the penicillin result.
5. For streptococci, refer to penicillin result.
6. The absence of resistant strains precludes the CLSI from defining any result categories other than "Susceptible" at this time. Strains yielding results
suggestive of a "non-susceptible" category should be submitted to a reference laboratory for further testing.
7. OTHER therapy based on Manufacturer's Breakpoints.
8. Only systemic therapy will be reported.
9. OTHER therapy based on Interpretive Breakpoints as indicated in the 2008 or 2012 Report of the Comité de l'Antibiogramme de la Société Française de
32
Microbiologie (CA-SFM).
10. OTHER therapy based on FDA breakpoints.
11. OTHER therapy based on MENSURA guidelines.
12. Only urine therapy will be reported.
NOTE: Interpretative criteria listed in the labeling may differ from the criteria in the LabPro Information Manager due to
differences in software and panel releases.
NOTE: Antimicrobial agents listed in the Interpretive Breakpoints table may not be available on every panel type.
C29870–AD
Abbr. S
Ofl
≤1
Ox
≤0.25
≤2
P
≤0.12
6
P/T
Prs
Rif
9
9
Syn
≤1
≤1
Tei
≤2
≤2
Te
≤1
≤1
Tim
To ≤1
T/S ≤2/38
Va
≤2
≤4
≤4
6
≤2
6
≤2
33
9 of 339
1
EUCAST
I R S
-
>1 ≤2
- - -
≤2
-
>0.25 ≤0.25
-
>2 ≤2
-
>0.12 ≤0.12
- - -
≤2
- - -
≤8
- - -
≤0.12
- - -
≤0.12
- - -
≤8
- - - -
- - -
≤1
- - -
≤1
- - - -
- - - -
2 >2 ≤1
- - -
≤1
-
2-4 >4
- - -
≤1
- - -
≤8
- -
>2
-
>2 ≤8
2 >2 ≤4
- - -
≤4
2 >2 ≤2
- - -
≤2
- - -
≤8
-
>1 ≤4
4/76 >4/76 ≤2/38
-
>2 ≤2
-
>4 ≤4
-
>4 ≤4
-
>2 ≤1
-
>2 ≤1
2
CLSI OTHER
I R S
-
4 ≥8
-
4 ≥8
- -
≥0.5
- -
≥4
- -
≥0.25
- - -
- -
≥16
- - -
-
0.25-2 ≥4
- -
≥16
- -
≤1
2 ≥4 ≤0.5 1-16
-
2 ≥4
- -
≤4 8-16
- -
≤4 8-16
-
2 ≥4
-
2 ≥4
- - -
-
2 ≥4
-
16 ≥32
- - -
-
16 ≥32
-
8 ≥16
-
8 ≥16
-
4 ≥8
-
4 ≥8
- -
≥16
-
8 ≥16
- -
≥4/76
-
4-8 ≥16
-
8-16 ≥32
-
8-16 ≥32
- - -
- - -
31
3
I R
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2 ≥4
≥32
- -
≥32
≥32
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -